Blood Transfusion Diagnostics Market Size

ID: MRFR/MED/0620-HCR

200 Pages

Rahul Gotadki

October 2025

Blood Transfusion Diagnostics Market Size, Growth Research Report By Product Type (Infectious Disease Testing, Blood Grouping Tests, Compatibility Testing, Nucleic Acid Testing), By Technique (Enzyme-Linked Immunosorbent Assay, Polymerase Chain Reaction, Chemiluminescent Immunoassay, Microbiological Techniques), By End User (Hospitals, Blood Banks, Diagnostic Laboratories, Academic Institutions) - Competitor Industry Analysis and Trends Forecast Till 2035

Blood Transfusion Diagnostics Market Infographic

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Blood Transfusion Diagnostics Size

Blood Transfusion Diagnostics Market Growth Projections and Opportunities

Since blood transfusions are needed worldwide, the blood transfusion diagnostics industry is growing. Many factors contribute to the growth in blood transfusions. Surgical operations, trauma, and anemia are examples. This issue has driven demand for diagnostic equipment and testing. The blood screening sector has been greatly impacted by technological advances. Blood transfusion diagnoses are improved by sophisticated screening technologies including nucleic acid testing (NAT) and enhanced immunoassays. This is done to fulfill the growing need for safe, trustworthy blood products. The market is affected by strict blood safety and transfusion diagnostics regulations. This is the result of constraints. Since regulatory organizations worldwide have set strict standards for screening given blood for infectious illnesses, the usage of modern diagnostic methods that meet these requirements has increased. Blood-donating organizations must undergo extensive screening due to the presence of blood-borne infections including HIV, hepatitis, and others. Diagnostics for blood transfusions are crucial because they identify and eliminate tainted blood units. This shields blood donors and receivers from health dangers. The market is growing due to increased awareness of safe blood transfusions and diagnostics' role in blood safety. This understanding helps keep blood safe. Healthcare institutions and government organizations are promoting transfusion diagnostic technology via education. Healthcare facilities run these programs. Blood supply problems, exacerbated by natural catastrophes and public health issues, highlight the need for effective and efficient blood transfusion diagnostics. Diagnostic tools that assure safe blood product availability amid shortages are growing in popularity. These technologies accelerate screening. Diagnostic technologies in healthcare systems are a major market driver. Automated and integrated transfusion diagnostics systems help hospitals and blood banks streamline blood transfusion services and testing. These systems improve testing efficiency. The amount of blood given is rising worldwide due to voluntary blood donation campaigns. Effective, high-throughput blood transfusion diagnostics will be needed as donor numbers grow. This will boost market growth. International blood transfusion disease control methods are changing the business world. WHO is leading blood safety programs. Healthcare institutions must invest in advanced transfusion diagnostics to screen effectively, according to the WHO. WHO leads these activities. The COVID-19 pandemic has affected the Blood Transfusion Diagnostics Market by highlighting the necessity for a robust and secure blood supply chain. Modern diagnoses have been hastened due to pandemic measures and screening. These procedures protect blood donors and recipients.

Blood Transfusion Diagnostics Market Size Graph

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected growth of the Blood Transfusion Diagnostics market?

The Blood Transfusion Diagnostics market is the expected increase in total market value of 17.59 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Blood Transfusion Diagnostics market?

Blood Transfusion Diagnostics market size was valued at approximately 9.37 billion USD in 2024. This figure will reach 17.59 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Blood Transfusion Diagnostics market?

Blood Transfusion Diagnostics market is expected to grow at a CAGR of 5.89% between 2025 and 2035.

How much will the Blood Transfusion Diagnostics market be worth by 2035?

Blood Transfusion Diagnostics market is expected to be worth of 17.59 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Blood Transfusion Diagnostics market perform over the next 10 years?

Over the next 10 years the Blood Transfusion Diagnostics market is expected to shift from usd billion 9.37 to 17.59 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the market size of the Blood Transfusion Diagnostics Market by 2035?

The Blood Transfusion Diagnostics Market was valued at 6.5 USD Billion by 2035.

Which region dominated the Blood Transfusion Diagnostics Market in 2024?

North America dominated the market with a valuation of 1.8 USD Billion in 2024.

What are the market values for the main product types in the Blood Transfusion Diagnostics Market in 2024?

In 2024, the main product types are valued as follows: Infectious Disease Testing at 1.5 USD Billion, Blood Grouping Tests at 1.2 USD Billion, Compatibility Testing at 1.1 USD Billion, and Nucleic Acid Testing at 0.69 USD Billion.

Who are the key players in the Blood Transfusion Diagnostics Market?

Major players in the market include Becton Dickinson, Beckman Coulter, bioMérieux, Thermo Fisher Scientific, and Roche Diagnostics.

The Blood Grouping Tests segment was valued at 1.2 USD Billion in 2024of the Asia Pacific region in 2035?

The projected market value of the Asia Pacific region is expected to reach 1.3 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Blood Transfusion Diagnostics Market was estimated at 9.37 USD Billion in 2024. The Blood Transfusion Diagnostics industry is projected to grow from 9.92 USD Billion in 2025 to 17.59 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.89 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Blood Transfusion Diagnostics Market is poised for substantial growth driven by technological advancements and regulatory focus.

Technological advancements are enhancing the accuracy and efficiency of blood transfusion diagnostics.
North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector.
Blood typing continues to dominate the market, whereas infectious disease testing is witnessing rapid growth.
The increasing prevalence of blood disorders and rising demand for safe blood transfusion practices are key drivers of market expansion.

Blood Transfusion Diagnostics Market

CAGR

5.89%

Market Size & Forecast

2024 Market Size	9.37 (USD Billion)
2035 Market Size	17.59 (USD Billion)
CAGR (2025 - 2035)	5.89%
Largest Regional Market Share in 2024	North America

Major Players

Grifols (ES), Roche (CH), Abbott (US), Terumo (JP), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Beckman Coulter (US), Siemens Healthineers (DE), Hologic (US)

Market Trends

The Blood Transfusion Diagnostics Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing emphasis on patient safety. The integration of automated systems and artificial intelligence is enhancing the accuracy and efficiency of blood testing processes. This evolution is not only streamlining operations but also reducing the risk of transfusion-related complications. Furthermore, the growing awareness of the importance of blood type compatibility and infectious disease screening is propelling the demand for sophisticated diagnostic tools. As healthcare providers strive to improve patient outcomes, the Blood Transfusion Diagnostics Market is poised for substantial growth. In addition, regulatory bodies are intensifying their focus on ensuring the safety and quality of blood products. This heightened scrutiny is likely to encourage innovation within the sector, as companies seek to develop cutting-edge solutions that comply with stringent guidelines. The market landscape is also witnessing a shift towards point-of-care testing, which offers rapid results and enhances the decision-making process in critical situations. Overall, the Blood Transfusion Diagnostics Market appears to be on a promising trajectory, with numerous opportunities for stakeholders to explore and capitalize on emerging trends.

Technological Advancements

The Blood Transfusion Diagnostics Market is witnessing a surge in technological innovations, particularly in automation and artificial intelligence. These advancements are enhancing the precision of blood testing and expediting the diagnostic process, thereby improving overall patient care.

Regulatory Focus

There is an increasing emphasis on regulatory compliance within the Blood Transfusion Diagnostics Market. Stricter guidelines are prompting companies to innovate and develop solutions that meet safety and quality standards, ultimately benefiting patient outcomes.

Shift to Point-of-Care Testing

The market is experiencing a notable shift towards point-of-care testing, which allows for immediate results and facilitates timely clinical decisions. This trend is likely to enhance the efficiency of blood transfusion processes and improve patient management.

Blood Transfusion Diagnostics Market Market Drivers

Growing Awareness of Blood Safety

There is a growing awareness of the importance of blood safety among healthcare providers and patients, which is driving the Global Blood Transfusion Diagnostics Market Industry. Educational campaigns and initiatives aimed at promoting safe blood transfusion practices are becoming more prevalent. This heightened awareness leads to increased demand for reliable diagnostic tools that can ensure the safety of blood products. As healthcare systems prioritize patient safety, the market for blood transfusion diagnostics is expected to benefit, with projections indicating a market value of 6.5 USD Billion by 2035, underscoring the long-term potential of this driver.

Regulatory Support and Guidelines

Supportive regulatory frameworks and guidelines established by health authorities are fostering growth in the Global Blood Transfusion Diagnostics Market Industry. Agencies such as the Food and Drug Administration and the European Medicines Agency are continuously updating regulations to ensure the safety and efficacy of blood transfusion diagnostics. These regulations encourage innovation and compliance among manufacturers, leading to the introduction of new diagnostic products. As a result, the market is likely to expand, with a projected compound annual growth rate of 3.42% from 2025 to 2035, reflecting the positive impact of regulatory support on industry growth.

Rising Demand for Blood Components

The increasing demand for various blood components, such as red blood cells, platelets, and plasma, is significantly influencing the Global Blood Transfusion Diagnostics Market Industry. Factors such as an aging population and the rise in surgical procedures contribute to this demand. For instance, the American Red Cross reports that blood donations are essential to meet the needs of patients undergoing surgeries or treatments for chronic illnesses. This growing requirement for blood components necessitates efficient diagnostic tools to ensure compatibility and safety, thereby propelling market growth in the coming years.

Increasing Prevalence of Blood Disorders

The rising incidence of blood disorders, such as hemophilia, thalassemia, and sickle cell anemia, is a pivotal driver for the Global Blood Transfusion Diagnostics Market Industry. As these conditions necessitate frequent blood transfusions, the demand for accurate and efficient diagnostic tools is expected to surge. For instance, the World Health Organization reports that millions of people worldwide suffer from these disorders, leading to an increased need for reliable transfusion diagnostics. This trend is anticipated to contribute significantly to the market's growth, with projections indicating a market value of 4.49 USD Billion in 2024.

Technological Advancements in Diagnostic Tools

Innovations in blood transfusion diagnostics, including the development of automated systems and advanced molecular techniques, are transforming the Global Blood Transfusion Diagnostics Market Industry. These advancements enhance the accuracy and speed of blood testing, thereby improving patient outcomes. For example, the introduction of next-generation sequencing and multiplex assays allows for the simultaneous detection of multiple pathogens in blood samples. Such technological progress not only streamlines the diagnostic process but also reduces the risk of transfusion-related infections, which is crucial for maintaining patient safety and trust in blood transfusion practices.

Market Segment Insights

By Application: Blood Typing (Largest) vs. Infectious Disease Testing (Fastest-Growing)

The Blood Transfusion Diagnostics Market exhibits a diverse application landscape, with Blood Typing commanding the largest share due to its critical role in ensuring safe transfusion practices. Infectious Disease Testing, while a smaller segment, is rapidly gaining traction as awareness and technologies improve, leading to an increase in its adoption across hospitals and blood banks. Cross-Matching, Compatibility Testing, and Antibody Screening play vital roles but are overshadowed by the aforementioned applications in market share distribution. In recent years, the growing prevalence of blood transfusions has fueled demand for reliable diagnostics, with Blood Typing being an essential element. Infectious Disease Testing, driven by heightened scrutiny surrounding transfusion-transmitted infections, is projected to grow at the fastest rate. Factors such as technological advancements in testing procedures, rising health regulations, and an aging population contribute significantly to the evolving dynamics of this segment.

Blood Typing (Dominant) vs. Antibody Screening (Emerging)

Blood Typing stands as the dominant force within the Blood Transfusion Diagnostics Market, delivering essential services that ensure compatibility and safety in blood transfusions. This application has become integral to both hospital protocols and blood donation centers, as proper blood group identification mitigates risk and enhances patient safety. On the other hand, Antibody Screening is emerging as a significant player, gaining momentum due to the increasing prevalence of sensitized patients, where prior blood exposure heightens the risk of transfusion reactions. As healthcare providers seek to improve transfusion safety and patient outcomes, the focus on effective Antibody Screening techniques is escalating, thereby marking its rising relevance in the diagnostics landscape.

By End Use: Hospitals (Largest) vs. Blood Banks (Fastest-Growing)

The Blood Transfusion Diagnostics Market reveals a significant distribution of market share among various end-use sectors. Hospitals currently dominate the market due to their extensive patient care and need for rapid diagnostic testing. Following closely are blood banks, which play a critical role in managing and securing blood supplies for transfusion. Diagnostic laboratories and research institutions are emerging as important players, although they command a smaller share compared to the primary sectors. Home care settings are gradually gaining traction as advancements in technology simplify at-home testing. Growth trends indicate a substantial increase in demand for blood transfusion diagnostics driven by factors such as rising incidences of blood-related disorders and a growing emphasis on patient safety. Hospitals are expanding their diagnostic capabilities, while blood banks are investing in newer technologies to enhance efficiency and accuracy. Emerging markets are also witnessing a rise in home care settings, with increasing patient preference for convenient testing solutions, thus significantly contributing to the market growth trajectory.

Hospitals (Dominant) vs. Blood Banks (Emerging)

In the Blood Transfusion Diagnostics Market, hospitals stand as the dominant segment, primarily due to their critical role in patient management and disease treatment. They provide comprehensive diagnostic services, equipped with advanced technology and trained professionals to ensure accurate blood testing and transfusion. On the other hand, blood banks are an emerging segment, focusing on improving blood collection, storage, and testing processes. They are becoming crucial in ensuring safe blood supplies, influenced by the increasing need for transfusions and the rise of donor awareness campaigns. Despite their smaller market share, blood banks are driving innovation in diagnostics to enhance safety and efficiency, creating a promising growth trajectory for the future.

By Product Type: Reagents (Largest) vs. Kits (Fastest-Growing)

In the Blood Transfusion Diagnostics Market, the segment of Reagents holds the largest market share due to their essential role in various testing and diagnostic procedures. Reagents are fundamental to ensuring accurate results in blood type identification and compatibility assessments, making them indispensable in laboratories and hospitals. In contrast, Kits are emerging as a rapidly growing segment within the market, driven by the increasing demand for point-of-care testing and the convenience they offer to healthcare practitioners.

Reagents (Dominant) vs. Kits (Emerging)

Reagents remain the dominant segment in the Blood Transfusion Diagnostics Market, providing crucial chemical solutions required for testing. Their widespread application in both major hospitals and smaller laboratories underscores their importance. As the cornerstone of various diagnostic procedures, reagents ensure the reliability of test outcomes, contributing to their sustained demand. Meanwhile, Kits are gaining traction as the emerging segment, offering comprehensive testing solutions that streamline the diagnostic process. These kits enable rapid testing in decentralized locations, catering to the rising preference for convenient and accessible healthcare solutions, particularly in rural and under-served areas.

By Technology: Molecular Diagnostics (Largest) vs. Immunoassays (Fastest-Growing)

In the Blood Transfusion Diagnostics Market, the Molecular Diagnostics segment holds the largest share, significantly outpacing other technologies like Immunoassays and Microbiology. Molecular Diagnostics represents a crucial technology for identifying and processing blood types and pathogens, thereby ensuring safer transfusions. Its prevalence can be attributed to the growing need for precise and accurate diagnostics, which is paramount in blood transfusion procedures. On the other hand, Immunoassays and other testing methods like Hemagglutination and Nucleic Acid Testing also contribute to this market, with Immunoassays emerging as a promising option due to technological advancements.

Immunoassays (Dominant) vs. Nucleic Acid Testing (Emerging)

Immunoassays have established themselves as a dominant technology in Blood Transfusion Diagnostics, known for their reliability and accuracy in detecting antibodies and pathogens in blood samples. This segment thrives on innovations that enhance test sensitivity and speed, catering to the increasing demand for swift results in transfusion settings. Meanwhile, Nucleic Acid Testing is viewed as an emerging technology, leveraging molecular techniques to offer even greater specificity in blood screening. Though currently smaller in market share, the ongoing advancements in nucleic acid methodologies position it for rapid growth as healthcare providers seek optimal solutions for transfusion safety.

Get more detailed insights about Blood Transfusion Diagnostics Market Research Report - Forecast to 2035

Regional Insights

North America : Market Leader in Diagnostics

North America is poised to maintain its leadership in the Blood Transfusion Diagnostics Market, holding a significant market share of 4.68 billion. The region's growth is driven by advanced healthcare infrastructure, increasing demand for blood transfusions, and stringent regulatory frameworks that ensure safety and efficacy. The rise in chronic diseases and the need for timely diagnostics further fuel market expansion. The United States stands as the largest contributor, with key players like Abbott, Grifols, and Hologic leading the charge. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. The presence of robust research institutions and a focus on technological advancements solidify North America's position as a hub for blood transfusion diagnostics.

Europe : Emerging Market Dynamics

Europe, with a market size of 2.8 billion, is witnessing a surge in demand for blood transfusion diagnostics driven by increasing healthcare investments and a growing aging population. Regulatory bodies are emphasizing the importance of safety and quality in blood transfusions, which is propelling the adoption of advanced diagnostic technologies. The region's focus on improving healthcare outcomes is a significant catalyst for market growth. Leading countries such as Germany, France, and the UK are at the forefront, with companies like Roche and Siemens Healthineers playing pivotal roles. The competitive landscape is marked by innovation and collaboration among key players, enhancing the availability of cutting-edge diagnostic solutions. As regulations evolve, the market is expected to adapt, ensuring compliance and fostering growth.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region, valued at 1.8 billion, is emerging as a significant player in the Blood Transfusion Diagnostics Market. Factors such as increasing healthcare expenditure, rising awareness about blood safety, and a growing population are driving demand. Governments are implementing policies to enhance healthcare infrastructure, which is expected to further boost market growth. The region's diverse healthcare needs present unique opportunities for diagnostic innovations. Countries like Japan, China, and India are leading the charge, with key players such as Terumo and Ortho Clinical Diagnostics making substantial contributions. The competitive landscape is evolving, with local companies increasingly entering the market, fostering innovation and affordability. As the region continues to develop, the demand for reliable blood diagnostics is set to rise significantly.

Middle East and Africa : Emerging Market Potential

The Middle East and Africa (MEA) region, with a market size of 0.09 billion, presents emerging opportunities in the Blood Transfusion Diagnostics Market. The growth is driven by increasing healthcare investments and a rising prevalence of blood-related disorders. Governments are focusing on improving healthcare access and quality, which is expected to enhance the demand for diagnostic solutions. Regulatory frameworks are gradually evolving to ensure safety and efficacy in blood transfusions. Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities adopting advanced diagnostic technologies. The competitive landscape is characterized by a mix of local and international players, creating a dynamic environment for growth. As healthcare systems improve, the demand for blood transfusion diagnostics is anticipated to rise, paving the way for new entrants and innovations.

Key Players and Competitive Insights

The Blood Transfusion Diagnostics Market is characterized by a dynamic competitive landscape, driven by technological advancements, regulatory changes, and an increasing demand for safe blood transfusions. Key players such as Grifols (ES), Roche (CH), and Abbott (US) are strategically positioned to leverage innovation and expand their market presence. Grifols (ES) focuses on enhancing its product portfolio through research and development, while Roche (CH) emphasizes digital transformation and automation in its diagnostic solutions. Abbott (US) is actively pursuing partnerships to enhance its testing capabilities, which collectively shapes a competitive environment that is increasingly reliant on technological prowess and strategic collaborations.

In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly crucial in a market that is moderately fragmented. The competitive structure allows for both established players and emerging companies to coexist, with key players exerting considerable influence over market trends and consumer preferences. This collective approach to operational efficiency and localized production is likely to enhance responsiveness to market demands.

In November 2025, Grifols (ES) announced a strategic partnership with a leading biotechnology firm to develop next-generation blood screening technologies. This collaboration is expected to enhance Grifols' capabilities in ensuring blood safety and could potentially lead to significant advancements in diagnostic accuracy. Such partnerships are indicative of a broader trend towards collaborative innovation in the industry.

In October 2025, Roche (CH) launched a new automated blood testing platform aimed at improving the efficiency of transfusion diagnostics. This platform integrates artificial intelligence to streamline workflows and reduce turnaround times for test results. The introduction of this technology not only positions Roche as a leader in automation but also reflects the growing importance of AI in enhancing diagnostic processes.

In September 2025, Abbott (US) expanded its global footprint by acquiring a regional diagnostics company specializing in blood transfusion technologies. This acquisition is likely to bolster Abbott's market share and enhance its product offerings, allowing for a more comprehensive approach to blood diagnostics. Such strategic moves underscore the importance of mergers and acquisitions in achieving competitive advantage in a rapidly evolving market.

As of December 2025, current trends in the Blood Transfusion Diagnostics Market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, the focus appears to be shifting from price-based competition to differentiation through innovation, technological advancements, and reliable supply chains. This evolution suggests that companies that prioritize these aspects will likely emerge as leaders in the market.

Key Companies in the Blood Transfusion Diagnostics Market market include

Industry Developments

Recent developments in the Blood Transfusion Diagnostics Market have showcased significant advancements and strategic movements among key players. Abbott Laboratories, Hologic, and have been focusing on enhancing their product portfolios through innovative technology and improved testing methods, leading to increased reliability and efficiencies in transfusion diagnostics.

In September 2023, Thermo Fisher Scientific announced the launch of a new molecular diagnostic platform, aiming to streamline blood screening processes. Roche has also expanded its offerings with a new automated testing solution, catering to a growing demand for accurate results.

Regarding mergers and acquisitions, Siemens Healthineers completed the acquisition of Varian Medical Systems in October 2020, strengthening its position in the diagnostics segment, although it is more focused on cancer care.

Additionally, Becton Dickinson made a strategic investment in a startup dedicated to blood collection technologies earlier this year, aiming at enhancing operational capabilities.

The market has been experiencing notable growth, driven by an increasing demand for safe blood transfusion practices and technological innovations, with expectations from industry authorities projecting consistent growth throughout the coming years.

Future Outlook

Blood Transfusion Diagnostics Market Future Outlook

The Blood Transfusion Diagnostics Market is projected to grow at a 5.89% CAGR from 2024 to 2035, driven by technological advancements, increasing demand for safe blood transfusions, and regulatory support.

New opportunities lie in:

Development of integrated blood screening platforms for hospitals
Expansion of mobile blood testing units for remote areas
Investment in AI-driven predictive analytics for transfusion compatibility

By 2035, the market is expected to achieve robust growth, driven by innovation and strategic investments.

Market Segmentation

Blood Transfusion Diagnostics Market End Use Outlook

Hospitals
Blood Banks
Diagnostic Laboratories
Research Institutions
Home Care Settings

Blood Transfusion Diagnostics Market Technology Outlook

Molecular Diagnostics
Immunoassays
Microbiology
Hemagglutination
Nucleic Acid Testing

Blood Transfusion Diagnostics Market Application Outlook

Blood Typing
Infectious Disease Testing
Cross-Matching
Compatibility Testing
Antibody Screening

Blood Transfusion Diagnostics Market Product Type Outlook

Reagents
Instruments
Software
Consumables
Kits

Report Scope

MARKET SIZE 2024	9.37(USD Billion)
MARKET SIZE 2025	9.92(USD Billion)
MARKET SIZE 2035	17.59(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.89% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Grifols (ES), Roche (CH), Abbott (US), Terumo (JP), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Beckman Coulter (US), Siemens Healthineers (DE), Hologic (US)
Segments Covered	Application, End Use, Product Type, Technology
Key Market Opportunities	Integration of advanced molecular diagnostics enhances safety and efficiency in the Blood Transfusion Diagnostics Market.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the Blood Transfusion Diagnostics Market.
Countries Covered	North America, Europe, APAC, South America, MEA